It is established that GLP-1R activation induces the stabilization of Nrf2, potentially via PKA or PKC, enabling its translocation to the nucleus (Fernandez-Millan et al., 2016
GLP-1s can result in considerable weight reduction, with individuals experiencing an average loss of 10-20% of their total body weight
Patients with type 2 diabetes and dyslipidaemia represent the most appropriate group for GLP-1 therapy when glycaemic targets are not achieved with other treatments
Take our Poll: Have you ever considered using Ozempic (semaglutide) to lose weight
Voerman E, Santos S, Inskip H, Amiano P, LifeCycle Project-Maternal O, Childhood Outcomes Study G, et al
Also, any information on retatrutide dosing for weight loss is based on current data, but research is ongoing and FDA approval is pending